Waystar surges after Q3 earnings beat, raises 2025 guidance
Healthcare payments software company exceeds analyst expectations as Iodine integration accelerates
Waystar Holding Corp. shares rallied in extended trading after the healthcare payments software company reported third-quarter results that exceeded analyst expectations and raised its full-year guidance, signaling continued momentum from its AI-powered platform and recent acquisition integration.
The company reported revenue of $268.7 million for the third quarter of 2025, representing a 12% increase year-over-year and surpassing analysts' expectations, according to Waystar's official results announcement. Non-GAAP earnings per share reached $0.37, beating the consensus estimate of $0.34 by three cents, while adjusted EBITDA grew 17% year-over-year to $112.7 million with an adjusted EBITDA margin of 42%.
Following the strong quarterly performance, Waystar raised its full-year 2025 guidance across key metrics. The company now expects total revenue between $1.085 billion and $1.093 billion, representing 15% year-over-year growth at the midpoint, according to analysis of the earnings call transcript. Adjusted EBITDA guidance was increased to between $451 million and $455 million, with non-GAAP net income expected in the range of $271 million to $274 million.
The raised guidance includes approximately $120 million of revenue contribution from the Iodine Software acquisition for the full year 2025, with about $30 million expected in the fourth quarter. Chief Executive Officer Matt Hawkins emphasized that the integration of Iodine, which specializes in clinical artificial intelligence for healthcare, is progressing ahead of plan, as reported by Seeking Alpha.
"Our results this quarter reflect accelerating demand for our AI-powered platform as healthcare providers increasingly seek technology solutions to simplify their revenue cycle operations," Hawkins stated during the earnings call. "The successful execution of our strategic priorities, including the Iodine integration, positions us well for sustained growth."
Despite the strong fundamentals, Waystar's stock performance has diverged significantly from analyst expectations. The shares currently trade at approximately $22, far below the 52-week high of $48.11 and representing a discount of more than 50% to the consensus analyst price target of $46.67, according to market data. Analyst sentiment remains overwhelmingly positive, with 21 firms rating the stock a buy or strong buy compared to just one hold recommendation.
The valuation disconnect comes as the broader software sector has experienced multiple compression in 2025, particularly for high-growth, unprofitable companies. However, Waystar's continued profitability expansion—with adjusted EBITDA margins of 42% in the third quarter—distinguishes it from many peers still burning cash to achieve growth.
Investors are now focused on the upcoming fourth-quarter and full-year 2025 earnings release, scheduled for February 17, 2026. Analysts currently expect Q4 revenue of approximately $294 million, representing a 20.7% increase from the year-ago quarter, with earnings per share estimates ranging from $0.19 to $0.39.
The company serves approximately 30,000 clients and processes more than 6 billion healthcare payment transactions annually, according to regulatory filings. Its cloud-based platform helps healthcare providers optimize financial performance while reducing administrative complexity in the payment process.
As Waystar approaches its fourth-quarter report, the key metrics to watch include Iodine integration progress, subscription revenue trends, and the company's ability to maintain margin expansion while scaling operations. The raised guidance suggests management confidence in these areas, though execution risks remain in a rapidly evolving healthcare technology landscape.